Quarterly report pursuant to Section 13 or 15(d)

12. Segments

12. Segments

3 Months Ended

Jun. 30, 2018

12. SEGMENTS

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

The following tables set forth certain information regarding our segments:

	Three Months Ended June 30,
	2018			2017
Revenues:
Aethlon	$	149,625		$	–
ESI		–			–
Total Revenues	$	149,624		$	–

Operating Losses:
Aethlon	$	(1,066,530	)	$	(1,141,406	)
ESI		(30,742	)		(18,843	)
Total Operating Loss	$	(1,097,272	)	$	(1,160,249	)

Net Losses:
Aethlon	$	(1,121,634	)	$	(1,826,708	)
ESI		(30,742	)		(18,843	)
Net Loss Before Non-Controlling Interests	$	(1,152,376	)	$	(1,845,551	)

Cash:
Aethlon	$	6,120,796		$	326,464
ESI		2,106			742
Total Cash	$	6,122,902		$	327,206

Total Assets:
Aethlon	$	6,451,635		$	492,324
ESI		2,106			16,827
Total Assets	$	6,453,741		$	509,151

Capital Expenditures:
Aethlon	$	–		$	23,705
ESI		–			–
Capital Expenditures	$	–		$	23,705

Depreciation and Amortization:
Aethlon	$	8,109		$	9,326
ESI		–			–
Total Depreciation and Amortization	$	8,109		$	9,326

Interest Expense:
Aethlon	$	(55,104	)	$	(188,604	)
ESI		–			–
Total Interest Expense	$	(55,104	)	$	(188,604	)